The GLP-1 Drug Landscape Changes on Thursday
The GLP-1 drug landscape is about to change. Starting Thursday, off-brand versions of semaglutide will no longer…
Blocked From Selling Off-Brand Ozempic, Telehealth Startups Embrace a Less Effective Drug
After telehealth startups recently lost the ability to sell exact copies of patented GLP-1 weight-loss drugs, some firms…
Patients Are Left With Few Options as GLP-1 Copycats Disappear
Futter’s provider, Henry Meds, no longer offers compounded tirzepatide injections, but allowed patients to place bulk orders before…
Former FDA Chief Praises ‘Revolutionary’ GLP-1s
“Revolutionary” anti-obesity drugs like Ozempic appear to be the right tool to deal with the addictive, highly…
Semaglutide Shows Major Promise for Treating Serious Liver Disease
Semaglutide, the active ingredient in popular drugs Ozempic and Wegovy, is poised to add to its growing list…
PGxAI Unveils AI Genetic Tool to Personalize GLP-1 Treatment
What You Should Know: – PGxAI, a leader in AI-powered pharmacogenomics released a new report aimed at personalizing…
Ozempic Linked to Lower Alzheimer’s Risk
Summary: A new study suggests that two widely used Type 2 diabetes medications—GLP-1 receptor agonists and SGLT2 inhibitors—may…